Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.39 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14069214 | 0.76 | SMARCA2 (0.46) | CNR1MAPTSMN1; SMN2GSK3AKDM4E | |
| SCHEMBL1752888 | 0.75 | ACHE (0.58) | CNR1TLR8MAPTSMN1; SMN2SOAT1 | |
| SCHEMBL1752878 | 0.73 | KCNH2 (0.40) | HSD11B1GPR84TLR8TSHRMAPT | |
| SCHEMBL1753128 | 0.72 | LMNA (0.46) | CNR1MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL15068306 | 0.72 | GCGR (0.53) | DHFRHSD11B1GPR84GCGRSOAT1 | |
| SCHEMBL15068263 | 0.72 | GCGR (0.53) | DHFRHSD11B1GPR84GCGRSOAT1 | |
| SCHEMBL10619914 | 0.71 | HSD11B1 (0.67) | HSD11B1GPR84MAPTSMN1; SMN2KDM4E | |
| SCHEMBL17144895 | 0.71 | HSD11B1 (0.50) | HSD11B1GPR84TLR8MAPTTP53 | |
| SCHEMBL11736750 | 0.71 | DHFR (0.50) | DHFRHSD11B1GPR84GCGRTLR8 | |
| SCHEMBL23205340 | 0.70 | RAB9A (0.52) | CNR1MAPTTP53SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367672-B2 | Pyridazine compounds, compositions and methods | UNIVERSITE DE STRASBOURG (FR) | 2013-02-05 | — | — | US | disclosed |
| US-20120245125-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | UNIVERSITE LOUIS PASTEUR DE STRASBOURG (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120157410-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | U.S. GOVERNMENT (US) | 2012-06-21 | — | — | US | disclosed |
| US-8158627-B2 | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100210590-A1 | COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2010-08-19 | — | — | US | disclosed |
| US-20090197885-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | UNIVERSITE DE STRASBOURG (FR) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197885-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | ACHE, BCHE, BACE1 | DHFR 344/4885HSD11B1 2042/4885GPR84 590/4885 |
| US-20120157410-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | ACHE, BCHE, BACE1 | DHFR 344/4885HSD11B1 2042/4885GPR84 590/4885 |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | APP, PSEN1, PSEN2 | DHFR 299/4885HSD11B1 2438/4885GPR84 1035/4885 |
| US-20120245125-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | DHFR 259/4885HSD11B1 2137/4885GPR84 1354/4885 |
| US-20100210590-A1 | COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS | C5, PNPO, CHRNA5 | DHFR 323/4885HSD11B1 2112/4885GPR84 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.